What is it about?
Although methotrexate (MTX) for rheumatoid arthritis (RA) sometimes causes severe haematological toxicities in users with chronic kidney disease (CKD), data are limited regarding the risk of these events and the preventive effect of folic acid.
Featured Image
Photo by Paweł Czerwiński on Unsplash
Why is it important?
ARN risk factors may differ between warfarin and DOACs. ARN risk may be associated with bleeding risk of warfarin and DOACs.
Perspectives
Better managing bleeding risk in patients taking anticoagulants may decrease the risk of ARN.
Dr Satoru Mitsuboshi
Read the Original
This page is a summary of: Risk of hematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: analysis of the Japanese Adverse Event Report database, British Journal of Clinical Pharmacology, November 2020, Wiley,
DOI: 10.1111/bcp.14641.
You can read the full text:
Contributors
The following have contributed to this page
